Company · BCRX
BioCryst Pharmaceuticals, Inc.
Nasdaq's symbol directory lists BCRX on Nasdaq as “BioCryst Pharmaceuticals, Inc. - Common Stock”.
In the 12 months to Nov 8, 2026: 2 filings by holders of 5% or more; 1 congressional trade disclosure; 1 company report (Form 8-K, since May 26, 2026).
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- RA Capital Management, L.P. 6.2%
- STATE STREET CORPORATION 6%
Congress · STOCK Act
The Althing
Periodic transaction reports. Amounts are the ranges members report; the trade date is when it happened, the report can come up to 45 days later.
- Gilbert Cisneros (D-CA31): Purchase $1,001 - $15,000
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Results of operations and financial condition; Regulation FD disclosure Nov 4, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.